Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 17, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
- Transaction Price: $48.40 per American Depositary Receipt (ADR).
- Transaction Type: Increase in interest via dividend re-investment.
- Dividend Payment Date: July 10, 2008.
Material Changes
The filing reports an increase in the Ordinary share ADR interests of Mr. D J Phelan, notified on July 16, 2008. This change resulted from the re-investment of dividends paid to shareholders. No other material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a specific insider transaction under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of ADRs held by Mr. D J Phelan following the July 16, 2008 transaction (reported as 178.83 units in the text).
- Confirm the dividend re-investment terms applicable to the GlaxoSmithKline Performance Share Plan.
- Review the full Disclosure and Transparency Rule 3.1.4R(1)(a) requirements to ensure complete compliance context.